GLP-1, GIP & Weight Management Medication FAQs — UK Guide to Safety, Nutrition & Support

GLP-1 medicines are prescription medicines that mimic or activate a hormone pathway involved in appetite, fullness, digestion and blood sugar control. In the UK, examples include semaglutide, tirzepatide and liraglutide, but each medicine has its own licence, patient leaflet and prescribing rules.

They should only be used when prescribed by a qualified healthcare professional and should not be used for cosmetic weight loss.

GLP-1 stands for glucagon-like peptide-1. It is a naturally occurring incretin hormone released by the gut after eating. GLP-1 helps signal fullness, supports insulin release when needed and slows how quickly food leaves the stomach.

GIP stands for glucose-dependent insulinotropic polypeptide. It is another incretin hormone involved in insulin response and energy balance. Tirzepatide is described as a dual GLP-1/GIP agonist because it acts on both receptor pathways.

They can reduce appetite, help people feel fuller for longer and slow stomach emptying. This can make it easier for some people to follow a reduced-calorie diet and healthier lifestyle plan. They are not magic weight-loss products and they work best as part of a medically supervised plan that includes nutrition, activity and behavioural support.

No. GLP-1 and GLP-1/GIP medicines are not insulin. They can affect insulin release and blood sugar control, but they work differently from insulin. People using insulin or other diabetes medicines should only combine them under professional supervision because blood sugar treatment may need review.

No. Some GLP-1 medicines are licensed for type 2 diabetes, some for weight management, and some for both. The licence depends on the active ingredient, brand, formulation and indication. A medicine used for diabetes is not automatically licensed for weight management.

These medicines can slow stomach emptying and influence appetite signals. Many people notice they become full after smaller portions, have less interest in large meals or feel uncomfortable if they eat too much or too quickly.

No medicine guarantees weight loss by itself. Diet quality, protein intake, movement, strength training, sleep, mental health, side effects, dose tolerance and long-term habits all matter. A medicine can be a tool, but the support around it is what helps make results safer and more sustainable.

No. UK medicines guidance is clear that these medicines are for specific medical disorders such as obesity, overweight with weight-related health problems or type 2 diabetes, depending on the licence. They are not intended for aesthetic or cosmetic weight loss.

Yes. GLP-1 and GLP-1/GIP medicines are prescription-only medicines in the UK. They must be prescribed by an appropriate healthcare professional after a proper assessment and supplied through a legitimate pharmacy or authorised healthcare route.

No. Do not buy prescription medicines from social media sellers, beauty salons, messaging apps, marketplaces or anyone offering them without a proper consultation. UK regulators have warned about fake and illegal weight-loss medicines that can cause serious harm.

For Great Britain, check the pharmacy on the General Pharmaceutical Council register. For Northern Ireland, check the Pharmaceutical Society of Northern Ireland. A real online pharmacy should make it clear who is prescribing, who is dispensing and how to contact them, and it should require a proper medical assessment before issuing prescription medicine.

Be extremely cautious. The MHRA warns that products supplied as powders in vials that must be mixed before injection are not authorised GLP-1 medicines and pose significant health risks. Genuine authorised products are supplied in approved forms, such as pre-filled pens or authorised tablets, depending on the medicine.

Yes. Counterfeit pre-filled pens can closely mimic licensed products. Packaging, batch numbers or images can look convincing. The safest route is a registered pharmacy and a valid prescription.

Prescription-only medicines must not be advertised to the public. This is why responsible UK content should stay educational, avoid inducements, avoid before-and-after promises, avoid celebrity-style endorsements and avoid implying that a consultation will result in a specific prescription medicine.

Prescription-only medicines should be prescribed because they are clinically suitable, not because they are discounted or promoted. Be cautious of urgency tactics, influencer codes, bulk deals, “limited-time” offers or adverts that make prescription medicines feel like ordinary retail products.

Do not use it. Contact the pharmacy or prescriber if it came from a legitimate service, seek medical advice if you have used it or feel unwell, and consider reporting concerns through the MHRA Yellow Card scheme or appropriate regulator.

No. Prescription medicines are prescribed for one person after individual assessment. Sharing pens, tablets or doses is unsafe and may expose another person to serious side effects, incorrect dosing or interactions with their medical conditions or medicines.

Some medicines may be available on the NHS for specific people who meet clinical criteria. Availability depends on the medicine, indication, location, NHS pathway, clinical need and current commissioning arrangements. NHS access for obesity medicines is being phased, so eligibility can change over time.

NICE is the National Institute for Health and Care Excellence. NICE reviews evidence and makes recommendations on whether medicines should be used in the NHS for particular conditions and patient groups. A NICE recommendation does not always mean everyone can access the medicine immediately; implementation and local pathways still matter.

Eligibility depends on the medicine and pathway. NICE guidance for tirzepatide includes an initial BMI of at least 35 kg/m² plus at least one weight-related comorbidity, with lower BMI thresholds usually applied for some ethnic backgrounds. NHS England is phasing access, so local services may prioritise people with greater clinical need first.

Examples commonly considered in NHS guidance include type 2 diabetes, high blood pressure, abnormal blood fats, obstructive sleep apnoea and cardiovascular disease. Your healthcare professional will assess your whole medical picture rather than using a single number alone.

Private prescribing may be available if a prescriber decides it is clinically appropriate after consultation. A safe private provider should review your medical history, BMI, current medicines, relevant conditions, pregnancy status, side-effect risks and follow-up plan before prescribing.

No. Safe private treatment still requires a healthcare consultation, a prescription and dispensing by a legitimate pharmacy. Avoid any seller that skips medical checks or promises medicine without assessment.

Your GP may be following NHS criteria, local pathway availability, phased rollout rules or clinical safety considerations. A person may meet a general licence description but still not meet current NHS commissioning criteria.

Wraparound care means support around the medicine, not just the prescription. It can include regular medication review, lifestyle support, nutrition advice, behavioural support, monitoring of side effects and help with long-term weight maintenance.

Speak to your GP, NHS service or private prescriber before changing supply route. They need to know your exact medicine, dose, response, side effects, medical history and monitoring needs. Do not run two supplies at once or change treatment without professional advice.

The active ingredient is the medicine substance, such as semaglutide or tirzepatide. The brand name is the marketed product name. Different brands with the same active ingredient may have different licences, doses, instructions and approved uses.

Semaglutide is a GLP-1 receptor agonist. In the UK, semaglutide products include brands used for different indications, such as weight management or type 2 diabetes. Always check the exact brand, formulation and patient leaflet.

Tirzepatide is a dual GLP-1/GIP receptor agonist. In the UK it is commonly associated with the brand Mounjaro and may be used for type 2 diabetes or obesity when prescribed appropriately and combined with diet and physical activity support.

They are associated with semaglutide, but they are not automatically interchangeable. They can have different licences, formulations, dosing instructions and intended uses. A medicine licensed for diabetes should not be treated as the same as a medicine licensed for weight management.

Mounjaro contains tirzepatide, which is a dual GLP-1/GIP receptor agonist. People often group it with GLP-1 medicines, but it acts on two incretin receptor pathways.

No. Many widely used products are injections, but tablet forms also exist for some semaglutide uses. In June 2026, the MHRA approved the first GLP-1 receptor agonist tablet for weight loss and weight management in the UK. Availability and NHS access should be checked through current official sources.

These are informal terms often used online. They can be misleading and may make prescription medicines sound like casual beauty treatments. Responsible UK guidance should use the correct medicine terms and emphasise prescription-only, medically supervised use.

Incretin medicines act on hormone pathways involved in food intake and blood sugar regulation. GLP-1 receptor agonists and dual GLP-1/GIP agonists are examples of incretin-based treatments.

No. A milligram amount in one medicine is not equivalent to a milligram amount in another medicine. The active ingredient, receptor activity, formulation and dosing schedule differ. Switching or dose comparison should only be done by a qualified healthcare professional.

People may be considered if they meet criteria for obesity, overweight with weight-related health conditions or type 2 diabetes, depending on the medicine licence and clinical pathway. A prescriber will assess BMI, health conditions, current medicines, previous treatments, risks and goals.

Anyone seeking to lose weight for appearance alone should not use prescription GLP-1 medicines. UK regulatory guidance is clear that these medicines are for specific medical disorders and should not be used just to become slimmer or change body shape.

Your history can affect suitability and safety. A prescriber may need to know about pancreatitis, gallbladder disease, kidney problems, diabetes complications, gastrointestinal disease, eye problems, allergies, eating disorders, mental health concerns, pregnancy plans and previous weight-management treatments.

Do not assume suitability. People with type 1 diabetes or complex diabetes care should only use medicines recommended by their diabetes specialist or prescriber. Blood sugar and insulin management can be affected and needs professional oversight.

This needs individual medical assessment. Pancreatitis is a serious condition and GLP-1 medicines carry warnings about acute pancreatitis. Tell your prescriber if you have ever had pancreatitis or severe unexplained abdominal pain.

Tell your prescriber. Weight loss itself and some medicines may be associated with gallbladder problems in some people. Symptoms such as severe upper abdominal pain, fever, yellowing of the skin or eyes, or pain after fatty meals should be assessed urgently.

Be open with your healthcare professional before starting. Reduced appetite, food rules, body-image pressure and rapid weight changes can be difficult for people with eating disorders or a history of restrictive eating, binge eating, purging or obsessive tracking. Extra psychological and dietetic support may be needed.

Age suitability depends on the medicine licence and specialist assessment. Do not give a young person any prescription medicine supplied for someone else. Parents or carers should speak to a GP or specialist service.

Some older adults may be suitable, but careful assessment is important. Reduced appetite, dehydration, muscle loss, frailty, kidney function, falls risk and interactions with existing medicines can matter more with age.

Ask why the medicine is suitable for you, what benefits are realistic, what side effects to expect, what symptoms need urgent help, how follow-up works, how long treatment may continue, how your current medicines are affected and what nutrition or activity support is recommended.

Give your full medical history, current medicines, supplements, allergies, previous weight-management treatments, pregnancy or breastfeeding status, contraception, mental health history, eating behaviour concerns, alcohol intake and any history of pancreatitis, gallbladder or kidney problems.

Your prescriber will decide. Depending on your health, they may consider checks such as HbA1c, kidney function, liver function, lipids, thyroid-related history, pregnancy testing or other assessments. Do not order unnecessary tests without clinical advice.

It can be useful to record your starting weight, waist measurement, blood pressure if relevant, energy levels, current eating pattern, protein intake, bowel habit, activity level and side-effect baseline. Avoid obsessive tracking if it harms your mental health.

Many people do better when they prepare simple, smaller meals, protein-rich foods, fluids and fibre before appetite drops. You do not need a crash diet. The goal is to make eating enough protein, fibre, vitamins and minerals easier when portions become smaller.

Ask your prescriber. Alcohol may worsen nausea, reflux, dehydration or blood sugar issues for some people. If you drink, keep it moderate and avoid using alcohol to replace meals or manage emotions.

It is sensible to plan fluids, fibre and movement early because reduced appetite and slower digestion can make constipation more likely. Increase fibre gradually, especially if you are prone to bloating, and seek advice if constipation is severe or persistent.

Do not panic-buy supplements. Focus first on a varied diet, protein, hydration and prescribed advice. A multivitamin, fibre support or meal replacement may be useful for some people, but check suitability if you take medicines, have kidney disease, are pregnant or breastfeeding, or have medical conditions.

A good goal is broader than the scale. It may include safer weight reduction, better blood sugar, improved blood pressure, more energy, better mobility, improved sleep, reduced waist measurement, stronger habits and preserving muscle mass. Agree realistic goals with your healthcare professional.

It depends on the medicine and formulation. Some are weekly injections, while some tablet forms are taken daily. Always follow the instructions on your prescription, packaging and patient leaflet.

Titration means gradually adjusting the dose under medical supervision. Many incretin medicines are started at a lower dose and increased step by step to help the body adjust and reduce side-effect risk. Do not increase faster than prescribed.

Discuss this with your prescriber. Some people may need slower increases or may remain on a tolerated dose for longer because of side effects, clinical response or personal circumstances. Dose decisions should be individual.

No. Do not increase early or take extra medicine. Appetite can fluctuate for many reasons, including stress, sleep, cycle changes, food choices and dose timing. Speak to your prescriber if appetite changes are affecting your plan.

Check the patient information leaflet for your exact medicine and contact a pharmacist or prescriber if unsure. Missed-dose rules differ between medicines and formulations. Do not take a double dose unless your own leaflet specifically tells you to.

Some weekly injections allow day changes under certain timing rules, but the safe interval depends on the medicine. Check your leaflet or ask your prescriber before changing your routine.

Many injection pens are used in fatty areas such as the abdomen, thigh or upper arm, depending on the medicine instructions. Rotate injection sites and follow the pen leaflet carefully. Ask a pharmacist, nurse or prescriber to show you if you are unsure.

No. Pens and tablets are prescribed to one person only. Using someone else’s medicine risks incorrect dosing, infection, allergic reaction, side effects and unsafe interactions.

Do not guess or repeat a dose without advice. Check the leaflet, contact the pharmacy or prescriber and keep the pen so they can advise. Taking extra medicine may increase side-effect risk.

No. GLP-1 medicines vary in strength, instructions, licence and side-effect profile. Switching without medical advice can increase side effects or make treatment less effective. Always involve a qualified healthcare professional.

Common side effects often involve the digestive system, such as nausea, vomiting, diarrhoea, constipation, reflux, burping, reduced appetite and abdominal discomfort. Tiredness, headaches and injection-site reactions can also occur with some medicines.

Many mild side effects improve as the body adjusts, especially after the early months or after dose changes. However, symptoms that are severe, persistent, worsening or worrying should be discussed with a healthcare professional.

Seek urgent help for severe stomach pain that may radiate to the back and does not go away, repeated vomiting, signs of severe dehydration, difficulty breathing, swelling of the face or throat, collapse, severe allergic reaction, sudden vision changes or symptoms that feel serious or unusual for you.

Possible warning signs include severe, persistent abdominal pain, often radiating to the back, sometimes with vomiting or feeling very unwell. Pancreatitis can be serious. Seek urgent medical advice rather than waiting for it to pass.

Yes. Vomiting and diarrhoea can lead to dehydration, especially if you are eating and drinking much less. Seek advice if you cannot keep fluids down, feel dizzy, pass very little urine, have confusion, a fast heartbeat or symptoms that are not settling.

Sudden vision loss, rapid worsening of eyesight or new serious eye symptoms need urgent medical advice. People with diabetes or existing eye disease should make sure their prescriber knows their eye history.

Low blood sugar is more likely if the medicine is used with insulin or certain diabetes tablets such as sulfonylureas. Symptoms can include sweating, shaking, palpitations, dizziness, confusion or feeling faint. Diabetes medicines may need review by a clinician.

Contact your prescriber or pharmacist if side effects make it difficult to eat, drink or function. Do not force large meals. Smaller, bland, protein-containing meals and fluids may help, but persistent symptoms need professional review.

Yes. You can report suspected side effects to the MHRA Yellow Card scheme. Reporting helps regulators monitor medicine safety, especially as usage patterns change.

Do not stop or restart prescription medicine without advice unless you have been told to do so or you are seeking urgent help for a serious reaction. Contact your prescriber so they can assess whether to pause, adjust, investigate or continue treatment.

Nausea can happen because these medicines slow digestion and affect appetite signals. It may be more noticeable after starting, after dose increases, after large meals, after high-fat meals or when you eat too quickly.

Many people find smaller portions, bland foods, plain carbohydrates, gentle protein foods, cold meals and sipping fluids easier. Examples include toast, crackers, plain rice, potatoes, porridge, Greek yoghurt, eggs, tofu or simple soups. Seek advice if nausea is persistent or severe.

High-fat meals can sit heavily in the stomach and may worsen nausea, reflux or fullness when stomach emptying is slower. Some people tolerate smaller amounts of healthy fats better than large greasy meals.

Try smaller meals, avoid lying down soon after eating, eat slowly, limit high-fat or very spicy meals if they trigger symptoms, and avoid eating late at night. Speak to a pharmacist or prescriber if reflux is frequent, severe or new for you.

Constipation can happen because digestion is slower, appetite is lower, fluid intake drops and fibre intake may fall when you eat smaller meals. Hydration, gradual fibre, fruit, vegetables, wholegrains and movement can help many people.

Many UK dietary resources suggest around 2 litres of water or low-calorie fluids a day for many adults, but your own needs may differ. Follow medical advice if you have heart failure, kidney disease, fluid restriction or another condition affecting fluid intake.

Yes, especially if increased too quickly. Add fibre gradually and drink enough fluid. If inulin, beans, lentils or fibre powders make symptoms worse, reduce the amount and build up slowly or ask a dietitian or pharmacist for advice.

Prioritise fluids and avoid dehydration. Small, simple meals may be easier. Seek medical advice if diarrhoea is severe, bloody, accompanied by fever, causes dehydration, or does not settle.

Many people feel full earlier than before. The aim is not to skip nutrition completely, but to make smaller meals count. Protein, fibre, vitamins, minerals and hydration become more important when portions are small.

Contact your prescriber if appetite loss makes you unable to eat enough or drink enough. Very low intake can increase tiredness, constipation, dehydration, nutrient shortfalls and muscle loss. A dietitian can help you build a tolerable eating plan.

Prioritise protein, fluids, fibre-rich foods, fruit and vegetables, and essential micronutrients. When volume is limited, each meal needs to work harder nutritionally. A “protein first, plants often, fluids daily” approach is a useful starting point.

Regular balanced meals are usually better than long periods without nutrition. Skipping meals can worsen nausea, tiredness, headaches, constipation and muscle loss for some people. Smaller meals or planned nutrient-rich snacks may be easier than large meals.

A practical plate might include a protein source, vegetables or salad, and a smaller portion of starchy carbohydrate such as potatoes, rice, oats, quinoa or pasta. Portion size may be smaller than before, but variety still matters.

People often find simple foods easier: eggs, Greek yoghurt, cottage cheese, tofu, fish, chicken, beans, lentils, soup, smoothies, oats, rice, potatoes, fruit, vegetables, protein shakes or light meal replacement drinks. Tolerance is individual.

Not automatically. Carbohydrates can provide energy, fibre and useful nutrients, especially from wholegrains, potatoes, oats, fruit, beans and lentils. The right amount depends on your diabetes status, goals, appetite and medical advice.

You do not need to avoid all fat. Healthy fats support nutrition and fat-soluble vitamins, but large high-fat meals can worsen nausea or reflux for some people. Smaller amounts may be better tolerated.

Choose smaller portions, ask for sauces on the side, prioritise lean protein and vegetables, avoid eating quickly, stop before you feel overfull and consider sharing a meal or taking leftovers home. Be cautious with alcohol and very rich meals if they trigger symptoms.

Cold meals, simple flavours, ready-to-eat protein foods and less aromatic options may be easier. Try well-ventilated cooking, batch-prepared mild foods or quick meals that reduce time around strong smells.

They can be useful for some people when normal meals feel too large or difficult, but they should not replace all food unless advised by a healthcare professional. Look for protein, fibre, vitamins, minerals and clear nutrition information, and check suitability with your prescriber if you have medical conditions.

When people lose weight, they can lose both fat and lean muscle. Protein helps maintain muscle, repair tissue, support fullness and make smaller meals more nutritious. Reduced appetite can make protein harder to reach, so planning matters.

Needs vary by body size, age, activity, health conditions and kidney function. Some NHS diet resources suggest 80–100 g protein daily for the general population using weight-loss medicines, but this is not right for everyone. Ask a dietitian or prescriber for personal guidance, especially with kidney disease.

Examples include eggs, fish, poultry, lean meat, Greek yoghurt, cottage cheese, tofu, tempeh, beans, lentils, chickpeas, edamame, Quorn-style products, protein powders or meal replacement drinks. Choose options you tolerate well.

Many people find it helpful to eat protein first when they get full quickly. This reduces the chance of filling up on low-protein foods and missing the nutrient most needed for muscle maintenance.

Strength training helps protect muscle, strength, balance and long-term metabolism while weight is changing. Even simple resistance bands, bodyweight exercises or supervised gym sessions can help. Start at a safe level and seek advice if you have injuries or medical conditions.

Fatigue may come from low calories, low fluids, low protein, poor sleep, side effects or overdoing activity. Start with gentle walking, mobility or short strength sessions, and review nutrition and hydration. Seek medical advice if tiredness is severe, persistent or unusual.

Yes. Rapid weight loss, very low protein, inactivity and under-eating can increase muscle loss. Warning signs may include weakness, poor stamina, dizziness, hair shedding, feeling cold, frequent illness or struggling with normal activities. Ask for professional support.

Food-first is ideal when possible, but protein shakes or meal replacements can be useful when appetite is low or meals are difficult. Choose products with clear nutrition information and avoid products claiming to work like prescription medicines.

NEAT means non-exercise activity thermogenesis: movement from daily life such as walking, chores, stairs and standing. As people eat less, they may unconsciously move less. Keeping everyday movement up can support energy, mood and maintenance.

Smaller food volume can mean fewer opportunities to get essential micronutrients. Over time, low intake can affect energy, hair, skin, immunity, mood, bone health and general wellbeing. A varied diet is the foundation, with supplements considered when appropriate.

The main risk is usually indirect: people may eat much less, eat less variety, avoid protein foods or skip meals due to nausea or fullness. This can make nutrient shortfalls more likely. Your healthcare professional may check for deficiencies if symptoms or risk factors are present.

Some people use a multivitamin and mineral product as a safety net when appetite is low, but it should not replace a balanced diet. Check with a healthcare professional if you are pregnant, breastfeeding, on blood thinners, have kidney disease or take prescribed medicines.

Fibre supports bowel regularity, gut bacteria, fullness and heart health. When appetite falls, fibre intake can drop, which may worsen constipation. Increase fibre gradually and pair it with fluid.

Electrolytes include minerals such as sodium, potassium and magnesium that help fluid balance, nerve function and muscle function. Vomiting, diarrhoea, sweating or very low intake can affect hydration and electrolytes. People with kidney, heart or blood pressure conditions should seek advice before using electrolyte products.

Headaches may relate to dehydration, low food intake, sleep changes, caffeine changes, side effects or other causes. Fluids, regular small meals and rest may help, but severe or persistent headaches should be assessed.

Some people find them useful, but start low and increase slowly to avoid bloating. Check ingredients and sugar alcohols if you are sensitive. Ask a pharmacist or dietitian if you have IBS, bowel disease, swallowing problems or take medicines that need spacing from fibre.

Yes. Supplements, herbal products and fortified formulas can interact with medicines or be unsuitable for certain conditions. Always tell your prescriber what you take, including “natural” products.

Look for useful protein, fibre, vitamins, minerals, clear calories, clear allergens, transparent ingredients and a responsible advisory statement. Avoid any product that claims to mimic, replace, boost or improve prescription GLP-1 medicines.

Some GLP-1 and GLP-1/GIP medicines are licensed for type 2 diabetes. They may help blood sugar control and weight management, but the exact medicine and plan should be decided by a diabetes clinician or prescriber.

Do not assume this is appropriate. Some products are licensed for diabetes but not weight management. Using a medicine outside its licence needs professional judgment and should not be driven by social media or product availability.

They can increase the risk of low blood sugar when combined with insulin or certain diabetes tablets. If you use diabetes medication, ask your clinician whether monitoring or dose changes are needed.

If you have diabetes, your clinician will advise. Monitoring may be especially important when starting, increasing dose, eating less, exercising more, drinking alcohol or adjusting other diabetes medicines.

Because these medicines can slow stomach emptying, they may affect how some oral medicines are tolerated or absorbed. Tell your prescriber about all medicines, especially narrow-therapeutic-index drugs or medicines where timing matters.

Yes. NHS medicine guidance highlights that some medicines, including warfarin, levothyroxine, insulin and other diabetes medicines, may need consideration. Do not adjust them yourself.

Ask your prescriber or pharmacist. Supplements can interact with medicines or worsen side effects such as drowsiness, stomach upset or changes in appetite. Always disclose CBD, herbal products, high-dose vitamins and sports supplements.

If you have diabetes, treat possible low blood sugar according to your diabetes care plan and seek advice. If symptoms are severe, recurrent or you are unsure what is happening, get medical help promptly.

Yes. Weight loss and reduced intake can affect blood pressure, diabetes control and other conditions. Your medicines may need review over time, so keep follow-up appointments and report dizziness, fainting or unusual symptoms.

GLP-1 medicines should not be taken during pregnancy or just before trying to get pregnant. There is not enough safety data to confirm safety for the baby. Speak to a healthcare professional straight away if you become pregnant while using one.

MHRA guidance gives wash-out periods that vary by medicine, such as at least 2 months for semaglutide and at least 1 month for tirzepatide. Always confirm your own medicine’s advice with your prescriber before planning pregnancy.

GLP-1 medicines should not be taken while breastfeeding because there is not enough safety data. Speak to your doctor, pharmacist or midwife about safer alternatives and timing.

MHRA guidance says people using Mounjaro who take an oral contraceptive should add a non-oral barrier method, such as condoms, for four weeks after starting and for four weeks after any dose increase, or consider a non-oral method after professional advice.

Contraception advice can vary by medicine and individual circumstances. If pregnancy is possible, discuss reliable contraception with your prescriber and read your patient information leaflet.

For some people, weight change may affect ovulation or fertility, which can increase the chance of pregnancy even if periods were irregular before. Use reliable contraception if pregnancy is not planned.

People with PCOS should discuss fertility, cycle changes, insulin resistance, contraception and pregnancy plans before treatment. Do not assume irregular periods mean pregnancy cannot happen.

Ask a healthcare professional for advice based on the specific medicine and personal health. Most public warnings focus on people who could become pregnant, but anyone planning conception should discuss medicines and supplements with a clinician.

Do not use meal replacements, high-dose supplements or specialist formulas in pregnancy or breastfeeding without professional advice. Needs are different during pregnancy and breastfeeding.

Yes. Tell your healthcare team, dentist, endoscopy team and anaesthetist before surgery, dental sedation, endoscopy or any procedure involving general anaesthesia or deep sedation.

GLP-1 medicines can slow stomach emptying. This may increase the risk that stomach contents could enter the airway during anaesthesia or deep sedation. Your team may need to adjust fasting instructions, timing or anaesthetic technique.

Do not stop without medical advice. MHRA guidance says to inform the healthcare team and continue prescribed medicines unless your doctor tells you otherwise. Your surgical team will advise based on the procedure and your risk.

Tell the emergency team when you last took the medicine, the dose, the brand and whether you have nausea, vomiting or reflux. Bring the packaging or medicine list if possible.

Yes if you are having sedation, complex treatment or if your dentist asks about medicines. Even routine dental teams should know your medication list, allergies and medical conditions.

Tell the endoscopy or bowel-preparation team. They may give specific instructions about medicines, fasting, fluids and bowel preparation. Do not guess because advice depends on the procedure.

Some people may be more prone to nausea or vomiting. Tell your team if you have had side effects, reflux or delayed stomach emptying symptoms. They can consider anti-sickness plans and hydration.

Write the active ingredient, brand name, dose, how often you take it and the date/time of your last dose. Also list diabetes medicines, blood thinners, supplements and allergies.

Storage depends on the medicine and whether the pen is unused or in use. Many pens require refrigeration before use and protection from heat or freezing. Always follow your own product leaflet and pharmacy label.

Usually yes, but plan ahead. Keep medicines in original packaging, carry a copy of your prescription or pharmacy label, check airline and destination rules, and use hand luggage where appropriate. Keep temperature-sensitive medicine within the leaflet’s storage range.

Hand luggage is often safer because checked luggage may be exposed to temperature extremes or get lost. Check airline rules and your medicine leaflet. Use a suitable cool pouch if needed, but do not freeze the medicine.

People who need injectable medicines can usually travel with medical needles, but carry them with the medicine, prescription evidence and original packaging. Check current airline, airport and destination rules before travel.

Use an approved sharps bin. Do not put needles in normal household rubbish or recycling. Ask your pharmacy, GP surgery or local council about local sharps disposal arrangements.

Do not use medicine if it has been stored outside the recommended conditions unless a pharmacist or manufacturer confirms it is safe. Contact your pharmacy for advice and keep the medicine packaging.

Alcohol may worsen nausea, vomiting, reflux, dehydration or blood sugar problems for some people. If you drink, keep it moderate and avoid drinking instead of eating. People with diabetes, pancreatitis risk or liver disease should seek individual advice.

Discuss fasting with your prescriber, especially if you have diabetes, take other medicines or are prone to dizziness or dehydration. Eating and drinking much less can increase side effects and blood sugar risks.

Consider original packaging, prescription label, needles, sharps container or travel sharps device, alcohol swabs if advised, cool pouch if needed, simple snacks, water bottle, electrolyte option if appropriate and contact details for your prescriber or pharmacy.

Appetite effects may appear earlier than visible weight changes, but results vary. Dose titration, side effects, lifestyle support, starting weight, biology, sleep, activity and adherence all influence progress.

Clinical results vary by medicine and person. Some NHS diet resources describe 10–20% body weight loss over two years when medicines are combined with healthy lifestyle choices, but not everyone achieves this and some people do not respond enough to continue.

Plateaus are common. As weight falls, energy needs change; appetite may return slightly; activity may drop; constipation can affect scale weight; and the body adapts. A plateau is not a reason to self-increase dose.

Review protein, fluid, fibre, meal consistency, alcohol, snacks, sleep, steps, strength training, constipation, stress and medication adherence. If the plateau persists, discuss it with your prescriber or dietitian.

Not everyone responds. NICE guidance includes reassessment points for some medicines, such as considering whether to continue if sufficient weight loss has not occurred after a defined time on the highest tolerated dose. Your clinician will weigh benefits, risks and alternatives.

Yes. Waist measurement, blood pressure, HbA1c, mobility, sleep, energy, clothes fit, fitness, joint comfort, appetite control and quality of life can all be meaningful markers.

Not necessarily. Very rapid loss can increase side effects, muscle loss, gallstone risk, fatigue and nutrient shortfalls. Safer progress includes nutrition, hydration, strength and medical monitoring.

No. Taking more than prescribed increases the risk of side effects and may be dangerous. Use the medicine exactly as prescribed and discuss concerns with your prescriber.

Appetite biology can change again when treatment stops or dose changes. Long-term habits, protein intake, strength training, behavioural support and maintenance planning are important to reduce regain risk.

Speak to your doctor before stopping. Stopping may affect appetite, weight and blood sugar, especially if you have type 2 diabetes. Some people may need a planned transition or alternative treatment.

It may. Many people notice appetite, cravings or portion tolerance increase after stopping or reducing treatment. A maintenance plan should start before stopping, not after regain has already happened.

Maintain regular meals, protein, fibre, strength training, daily movement, sleep routines, self-monitoring and behavioural support. Plan for hunger returning and build meals that keep you satisfied without relying only on willpower.

Do not pause and restart without advice. Restarting after a gap may require clinical guidance because tolerance and dose safety can change. Ask your prescriber before holidays, surgery, pregnancy plans or supply issues.

Contact your prescriber or pharmacy. Do not substitute a different brand, buy from unregulated sellers or stretch doses without advice. Supply interruptions need a safe plan.

Possibly, but only under professional guidance. Your previous dose may not be suitable after a break. Medical history, side effects and current medicines need review.

Yes, long-term nutrition remains important. Protein, fibre, micronutrients, meal structure and strength training help protect maintenance whether or not you remain on medication.

Yes. Weight loss can change blood pressure, diabetes control, sleep apnoea, fertility, medication needs and nutrient status. Follow-up helps adjust the plan safely.

Food noise is a non-medical phrase people use for frequent thoughts, urges or preoccupation around food. Some people report that appetite-changing medicines reduce this, but long-term coping skills, regular nutrition and mental health support still matter.

Mood can be influenced by many factors: eating less, body changes, side effects, sleep, stigma, blood sugar, alcohol, stress and mental health history. Speak to a healthcare professional if your mood changes, anxiety worsens or you feel emotionally unsafe.

Seek urgent help now. In the UK, call 999 if there is immediate danger, contact NHS 111 for urgent medical advice, speak to your GP crisis service, or contact Samaritans on 116 123. Do not wait for a routine medication review.

Yes. Eating very little may feel easy at first but can harm energy, muscles, bowels, hair, mood and nutrient status. If you are proud of not eating, afraid to eat, or feel guilty after normal meals, seek support.

Use broader progress markers, agree a weighing schedule with your clinician and avoid daily weighing if it harms your mood. Focus on habits you can control: meals, fluids, movement, sleep and follow-up.

Body comments can be triggering even when meant positively. You are allowed to set boundaries, such as “I’m focusing on my health and would rather not discuss my weight.” Support from trusted people can help.

Some people with binge eating may be considered under specialist care, but medication alone is not a complete treatment for eating behaviour. Psychological support, regular eating and relapse planning may be important.

Reduced appetite may temporarily lower urges, but emotions still need coping strategies. Consider journaling, therapy, stress management, sleep support, walking, structured meals and asking for help before old patterns return.

Yes. People can feel judged for using medication or judged for their weight. Obesity is complex and medical treatment can be appropriate for some people. Compassionate, evidence-based support is more useful than shame.

No. Foods, fibre, protein and some nutrients may influence normal fullness signals, but they are not the same as prescription GLP-1 or GLP-1/GIP medicines. Avoid products claiming to work like injections, replace medicines or produce prescription-like effects.

No responsible supplement should claim to replace prescription medicine. If you are eligible for medical treatment, discuss options with a qualified healthcare professional. Nutrition support can support diet quality, but it is not medication.

Be cautious. UK regulators warn against unauthorised products, including powders and vials. Do not use compounded, research chemical or “peptide” products bought online unless they are part of a legitimate, regulated healthcare route.

Do not copy microdosing advice from social media. Dose schedules are designed around evidence, safety and tolerability. If you need a lower or slower plan, ask your prescriber.

Do not use unofficial click-counting or dose-splitting methods unless your prescriber and patient leaflet clearly support the method for your exact pen. Unofficial dosing can lead to underdosing, overdosing or contamination risk.

Not always. Lighting, timing, posing, dehydration, editing and selective results can be misleading. They also do not show side effects, muscle loss, mental health, lab markers or long-term maintenance.

Be cautious. Prescription medicine decisions should not be driven by affiliate codes or influencer content. Use registered healthcare services and evidence-based information.

Do not combine prescription medicines with stimulant fat burners, laxatives, diuretics or appetite suppressants without medical advice. These can increase dehydration, heart symptoms, anxiety, digestive problems and other risks.

If a claim promises rapid weight loss, no consultation, celebrity results, medicine without prescription, “same as Mounjaro/Wegovy”, powders to mix yourself, or guaranteed side-effect-free results, treat it as a red flag.

In June 2026 the MHRA announced approval of the UK’s first GLP-1 receptor agonist tablet for weight loss and weight management. Like other GLP-1 medicines, it is prescription-only. NHS availability depends on further assessment and commissioning decisions.

Some people may prefer tablets, but tablets can have strict timing and fasting instructions and may not suit everyone. Suitability, availability and effectiveness should be discussed with a prescriber.

Do not switch without medical advice. Different formulations have different instructions, licences and dose conversions. Your prescriber must decide whether a switch is appropriate.

This is an active area of medicine development. New formulations, new active ingredients and new indications may be approved over time. Always check current MHRA, NHS and NICE information rather than relying on old articles.

Be cautious. Prescription-only medicines and unlicensed medicines should not be promoted to the public. Use legitimate healthcare providers and avoid services that market future prescription medicines aggressively.

No. GLP-1 tablets can still have side effects such as nausea, diarrhoea, constipation or vomiting, and they still require prescription supervision and patient leaflet instructions.

BMI stands for body mass index. It compares weight and height and is often used in medicine-access criteria. It does not tell the full story of health, but it is commonly used alongside weight-related conditions and clinical judgment.

A comorbidity is another health condition that exists alongside the main condition. In obesity medicine, examples may include type 2 diabetes, high blood pressure, abnormal blood fats, sleep apnoea or cardiovascular disease.

The patient information leaflet is the official leaflet supplied with a medicine. It explains how to use it, missed-dose advice, storage, side effects, warnings and who should not use it. Always read the leaflet for your exact medicine.

The MHRA Yellow Card scheme is the UK system for reporting suspected side effects or medicine safety concerns. Patients, carers and healthcare professionals can report.

The General Pharmaceutical Council register lets people check whether a pharmacy in Great Britain is registered. This is an important safety step before using an online pharmacy.

The Pharmaceutical Society of Northern Ireland register is used to check pharmacy registration in Northern Ireland.

Off-label use means a medicine is used outside the exact terms of its licence. Off-label prescribing can sometimes be clinically appropriate, but it requires professional judgment and informed discussion. It should not be driven by social media demand.

It means the dose a person can use while balancing benefit and side effects. The highest tolerated dose is not always the maximum possible dose. Prescribers may slow down, pause or avoid increases when side effects are significant.

Useful official sources include MHRA GLP-1 safety guidance, NHS medicines pages, NICE guidance, NHS England medicines for obesity updates, the GPhC register, PSNI register and the MHRA Yellow Card scheme. Links are included in the official resources panel below.

Review at least every 3 months, and sooner if MHRA, NHS, NICE, ASA/CAP or product labels change. GLP-1 guidance is evolving quickly, so keep a visible “last updated” date on the page.